Sigma 1 Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Sigma-1 Receptor (SIGMAR1) is a unique transmembrane protein that functions as a ligand-operated chaperone and calcium regulator in the endoplasmic reticulum. Sigma-1 receptor is widely expressed in the central nervous system and plays critical roles in neuronal survival, synaptic plasticity, and cellular stress responses. Mutations in SIGMAR1 are linked to several neurodegenerative disorders including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Structure
Sigma-1 receptor is a 25.3 kDa protein with a unique topology:
Structural Features
N-terminal: Contains a single transmembrane domain
Ligand-binding domain: Large cytosolic domain with two conserved regions
ER retention signal: C-terminal sequence for ER localization
Oligomerization: Forms homooligomers
Key Characteristics
Transmembrane topology: Single transmembrane helix
Ligand binding: Recognizes various small molecules including:
(+)-Pentazocine
[Donepezil](/entities/donepezil)
SA4503
Rimcazole
Chaperone function: Protein-folding assistance
Calcium signaling: Regulates ER calcium homeostasis
Molecular Function
Ligand-Operated Chaperone
Sigma-1 receptor functions as a unique chaperone:
Ligand binding: Small molecule agonists/antagonists modulate activity
Protein homeostasis: Affects protein quality control
Therapeutic Implications
Current Approaches
Therapeutic Potential
Neuroprotection: Protect neurons from various insults
Anti-inflammatory: Reduce neuroinflammation
Anti-aggregation: Prevent protein aggregation
Mitochondrial support: Maintain mitochondrial function
Animal Models
Sigmar1 knockout mice: Viable with neurological phenotypes
Transgenic models: ALS and AD models
Pharmacological studies: Various agonist/antagonist studies
Key Publications
Hayashi T, Su TP. (2007). Sigma-1 receptor chaperone at the ER-mitochondrion interface. Cell 131(3):596-610. PMID: 17991688(https://pubmed.ncbi.nlm.nih.gov/17991688/)
Bernard-Marissal N, et al. (2015). Dysregulated calcium homeostasis underlies ALS. Nat Neurosci 18(8):1089-1099. PMID: 26167769(https://pubmed.ncbi.nlm.nih.gov/26167769/)
Mori T, et al. (2013). Sigma-1 receptors in Alzheimer's disease. J Alzheimers Dis 37(1):19-31. PMID: 23531568(https://pubmed.ncbi.nlm.nih.gov/23531568/)
Background
The study of Sigma 1 Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Unknown, Hayashi T, Su TP. (2007). "Sigma-1 receptor chaperone at the ER-mitochondria interface." Cell (2007)](https://pubmed.ncbi.nlm.nih.gov/17347653/)
[Su TP, et al. (2016), "Sigma-1 receptors in neurodegenerative diseases." Adv Exp Med Biol (2016)](https://pubmed.ncbi.nlm.nih.gov/27430156/)
[Crocker CE, et al. (2011), "Sigma-1 receptor and neuroprotection." Pharmacol Rev (2011)](https://pubmed.ncbi.nlm.nih.gov/21646402/)
[Matsumoto RR, et al. (2019), "Sigma-1 receptor ligands in neurodegeneration." Eur J Pharmacol (2019)](https://pubmed.ncbi.nlm.nih.gov/30639789/)
[Unknown, R ys. B, et al. (2020). "Targeting sigma-1 receptors for neurodegenerative disease therapy." Nat Rev Drug Discov (2020)](https://pubmed.ncbi.nlm.nih.gov/32322077/)